SARS-CoV-2 vaccination response in patients with haematologicaldisease - CovVhaem

MUMC0 个研究点目标入组 743 人开始时间: 2021年3月10日最近更新: 2021年3月17日

试验速览

暂无简介。

•all of the following
•Currently treated, previously treated and non-treated patients
•diagnosed with a hematological malignancy (defined as: multiple myeloma (including MGUS) chronic lymphocytic leukemia, chronic myeloid leukemia, acute myeloid leukemia, acute lymphocytic leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, myelodysplastic syndrome, myeloproliferative disease).
•Previously treated patient is defined as: treatment < 6 months before vaccination in patients that obtained a complete remission. Exceptions (no time restriction for last treatment) are patients with palliative treatment for ongoing haematological malignancies and patients after autologous and allogeneic stem cell transplantation.
•Patients who are scheduled for and will undergo SARS-CoV-2
•vaccination.
•Aged = 18 years.
•Written informed consent.
•Inclusion is irrespective of previously proven or possible (based on
•symptoms) COVID-19
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 446
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 288

•excluded from participation in this study:
•Patients previously vaccinated for SARS-CoV-2.
•Patients who have senile dementia, mental impairment or any other psychiatric disorder that prohibits the patient from understanding and giving informed consent.
•Any psychological, familial, sociological or geographical condition
•potentially hampering compliance with the study protocol.

发起方